Clinical Trial Update: Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA) [Phase 2]

View source ↗

Summary

A Phase 2 randomized trial comparing fostamatinib monotherapy to adalimumab monotherapy in rheumatoid arthritis was terminated, with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• ADALIMUMAB (ADALIMUMAB-AATY)
• Fostamatinib (fostamatinib)

Snippet

Sponsor: AstraZeneca | Conditions: Rheumatoid Arthritis | Phase 2 | Status: TERMINATED | Results posted: 2014-05-06